About

What we do

We track the GLP-1 category — the drugs (semaglutide, tirzepatide, liraglutide), the telehealth providers prescribing them, the cost and insurance landscape, the regulatory developments around compounded versions, and what happens when patients stop. Every claim is sourced to a primary study, a regulatory notice, or a dated provider page. We do not write opinion pieces dressed up as evidence.

What we don’t do

We are not a telehealth provider. We do not prescribe, dispense, or fulfil orders. We do not employ clinicians. We do not collect health data and we will not ever sell one. If you need a prescription, you need a licensed prescriber — not us.

The publisher

Metabolic Ledger Publishing LLC publishes this site. The publisher is a small, independently held US company. We are not owned, funded, or operated by a telehealth platform, a drug manufacturer, an insurer, or a pharmacy. We have no investors who would benefit from a particular provider winning. We will name any material change to that ownership structure on this page within fourteen days.

The editorial team

We are recruiting a Registered Dietitian Nutritionist (RDN) to lead editorial. Until that hire is announced here by name and credential, articles are labelled as editorial contentand we don’t present them as nutrition advice. The masthead policy is simple: real people, real credentials, named in public. No house pseudonyms, no “Editorial Team” bylines hiding a single author.

Medical review

We are recruiting a US-licensed physician — ABOM-certified in obesity medicine — to medically review the clinical pages. Articles carry one of three explicit labels:

• Medically reviewed by [Name], MD — a named physician has reviewed this article for clinical accuracy.
• Awaiting medical review — substantive clinical content the reviewer has not yet read; flagged so you know.
• Editorial content— reporting on public information (regulatory notices, provider pricing, FDA filings); not clinical advice and not in the reviewer’s queue.

We don’t use stock physicians, generic “our medical board” pages, or backdated review dates. When the reviewer is announced, we will publish their CV link, the dates they joined, and the protocol that governs which pages they sign off on.

How we’re funded

We earn affiliate commissions from some — not all — of the telehealth providers we cover, plus from adjacent products (continuous glucose monitors, food-tracking apps, certain supplements). When a link earns us a commission, we say so next to that link, not in a footer disclaimer three pages away. We score providers on a published rubric; that score is not adjustable by the affiliate relationship. A provider that pays us nothing can still score top of the comparison. A provider that pays us well can still be flagged as the wrong choice for your situation. See our editorial policy for the firewall.

Who we write for

Our reader is somewhere in the GLP-1 decision: weighing whether to start, comparing the providers, working through the side effects, looking at the cost path, or — increasingly — figuring out what happens at month eighteen when the prescription stops. We are particularly opinionated about that last group. The off-ramp is the part the category does not want to talk about, and it is most of what your year-three outcome will be decided by.

Where to start

New here? Read how we evaluate providers and cite sources, then our editorial policy— the rules we hold ourselves to and the corrections we’ve issued. If you have spotted a mistake or want to flag a missing source, the contact page tells you where to send it.